Concepedia

Edward B. Garon

EB

220

Publications

51.6K

Citations

71

H-Index

2005

Active since

Affiliations

University of California, Los Angeles(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Memorial Sloan Kettering Cancer Center

Dana-Farber Cancer Institute

German Center for Lung Research

Edward B. Garon is an author at University of California, Los Angeles specializing in medicine, oncology, and cancer therapeutics.

ORCID

Top concepts

Publications per year

2005–2024

220

Publications

220

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder et al. · Science · 2015 · 7.8K citations · Full text

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst, Paul Baas, Dong‐Wan Kim et al. · The Lancet · 2015 · 6.4K citations

, , +7

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel et al. · New England Journal of Medicine · 2018 · 6.4K citations · Full text

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.1K citations · Full text

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Mark G. Kris, Bruce E. Johnson, Lynne D. Berry et al. · JAMA · 2014 · 1.7K citations · Full text

Rows per page

1–5 of 220